AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30813767 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD and booklet (DVDB)
Number of subjects: 393
Study 30813767 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 393
Study 28864922 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 215
Number of subjects: 202
Study 28864922 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (US)
Number of subjects: 202
Study 28864922 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (EU)
Number of subjects: 202
Study 25251166 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session 12-month sweetened beverages decrease intervention or comprehensive dietary and physical activity intervention
Number of subjects: 172
Study 25251166 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage only intervention
Number of subjects: 172
Study 25251166 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 172
Study 23956024 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention
Number of subjects: 755
Study 23956024 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 755
Study 20665554 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct screening (invitation by letter followed by a home visit to administer the GDS-15)
Number of subjects: 10681
Study 20665554 — intervention group
Group type: COMPARATOR
Intervention: Stepped screening (GDS-15 sent by post, home visit if score ≥4)
Number of subjects: 10681
Study 20665554 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct screening
Number of subjects: 10681
Study 20665554 — intervention group
Group type: COMPARATOR
Intervention: Stepped screening
Number of subjects: 10681
Study 19644132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral nutritional supplement containing 1.3 mg of riboflavin for 6 weeks
Number of subjects: 297
Study 19644132 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 297
Study 17442999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with vinorelbine and cisplatin
Number of subjects: 155
Study 17442999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 155
Study 17442999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 155
Study 17442999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vinorelbine and cisplatin)
Number of subjects: 155
Study 17442999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmalignant causes of death
Number of subjects: 155
Study 15036680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10mg (can be increased to 20mg or decreased to 5mg)
Number of subjects: 1173
Study 11331444 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal mesh hernia repair (TAPP) and laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study 11331444 — intervention group
Group type: COMPARATOR
Intervention: Open tension-free hernia repair and laparoscopic cholecystectomy (LC)
Number of subjects: 64
Study 9487208 — intervention group
Group type: EXPERIMENTAL
Intervention: 35-picosecond pulses from neodymium:YAG laser
Number of subjects: 16
Study 9487208 — intervention group
Group type: COMPARATOR
Intervention: 10-nanosecond pulses from neodymium:YAG laser
Number of subjects: 16
Study 7945998 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 0
Study 7945998 — intervention group
Group type: COMPARATOR
Intervention: danazol
Number of subjects: 0
Study 2740299 — intervention group
Group type: EXPERIMENTAL
Intervention: School and community-based program for prevention of cigarette, alcohol, and marijuana use
Number of subjects: 4664
Study 2740299 — intervention group
Group type: COMPARATOR
Intervention: Health education as usual
Number of subjects: 4664
Study 31103370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Number of subjects: 78
Study 31103370 — intervention group
Group type: COMPARATOR
Intervention: mNICE diet
Number of subjects: 78
Study 31034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 949
Study 31034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 949
Study 31034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate pain management
Number of subjects: 949
Study 31034245 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate sedation management
Number of subjects: 949
Study 28728183 — intervention group
Group type: EXPERIMENTAL
Intervention: Early focal laser photocoagulation
Number of subjects: 58
Study 28728183 — intervention group
Group type: COMPARATOR
Intervention: Sham laser
Number of subjects: 58
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 2.5 μg BID
Number of subjects: 206
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg QD
Number of subjects: 206
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg BID
Number of subjects: 206
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg QD
Number of subjects: 206
Study 26177937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg QD vs Olodaterol 2.5 μg BID
Number of subjects: 206
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg QD vs Olodaterol 5 μg BID
Number of subjects: 206
Study 26177937 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning and evening peak expiratory flow, Asthma Control Questionnaire scores
Number of subjects: 206
Study 23500245 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive medical therapy alone
Number of subjects: 0
Study 23500245 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical therapy with prompt revascularization
Number of subjects: 0
Study 21690555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAraC)
Number of subjects: 459
Study 21690555 — intervention group
Group type: COMPARATOR
Intervention: Timed-sequential chemotherapy (TSC)
Number of subjects: 459
Study 19428033 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-fed condition
Number of subjects: 7
Study 19428033 — intervention group
Group type: COMPARATOR
Intervention: 67-hour water-only fast
Number of subjects: 7
Study 16394691 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic single-use laryngoscope blades
Number of subjects: 284
Study 16394691 — intervention group
Group type: COMPARATOR
Intervention: Metal reusable laryngoscope blades
Number of subjects: 284
Study 15245344 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 884
Study 15245344 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 884
Study 11993024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine
Number of subjects: 90
Study 11993024 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric Bupivacaine
Number of subjects: 90
Study 8994413 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 40
Study 8994413 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 40
Study 8192452 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin with sucralfate (1 g)
Number of subjects: 8
Study 8192452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin with sucralfate (1 g)
Number of subjects: 8
Study 8192452 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin or ofloxacin given 2 h before sucralfate
Number of subjects: 8
Study 8192452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative recovery of norfloxacin in urine
Number of subjects: 8
Study 8192452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative recovery of ofloxacin in urine
Number of subjects: 8
Study 3074277 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 40
Study 3074277 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-imidazole-carboxamide-phosphate
Number of subjects: 40
Study 3074277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29497177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure (INP) + standard wound care (SWC)
Number of subjects: 9
Study 29497177 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (SWC) alone
Number of subjects: 9
Study 27178479 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion with standard care
Number of subjects: 190
Study 27178479 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 190
Study 25503585 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 3405
Study 22429513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation adenotonsillectomy
Number of subjects: 100
Study 22429513 — intervention group
Group type: COMPARATOR
Intervention: Dissection adenotonsillectomy
Number of subjects: 100
Study 19497032 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised stretch sessions for hamstring muscles, 30 min, five times a week for 6 weeks
Number of subjects: 60
Study 19497032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretch sessions)
Number of subjects: 60
Study 18566197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA) with 0.75% ropivacaine intraoperatively and 0.2% ropivacaine postoperatively for 48 hours
Number of subjects: 50
Study 18566197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 50
Study 18566197 — intervention group
Group type: COMPARATOR
Intervention: Control group (patient-controlled analgesia morphine)
Number of subjects: 50
Study 15788122 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein group (30 g/d protein)
Number of subjects: 113
Study 15788122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 11954675 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental medication
Number of subjects: 0
Study 10081516 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 265
Study 10081516 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 265
Study 8626174 — intervention group
Group type: EXPERIMENTAL
Intervention: Salinum
Number of subjects: 20
Study 8626174 — intervention group
Group type: COMPARATOR
Intervention: MAS‐84
Number of subjects: 20
Study 2215987 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injection for induction of anesthesia
Number of subjects: 0
Study 2215987 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of Diprivan (Propofol) for maintenance of anesthesia
Number of subjects: 0
Study 2215987 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone combined with enflurane
Number of subjects: 0
Study 398350 — intervention group
Group type: EXPERIMENTAL
Intervention: lofepramine
Number of subjects: 30
Study 398350 — intervention group
Group type: COMPARATOR
Intervention: mianserin
Number of subjects: 30
Study 31935754 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT after radiochemotherapy
Number of subjects: 0
Study 31935754 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 0
Study 31935754 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/MRI
Number of subjects: 0
Study 31087325 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of micronized vaginal progesterone once daily from 16-26 weeks until 36 weeks of gestation
Number of subjects: 109
Study 31087325 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily from 16-26 weeks until 36 weeks of gestation
Number of subjects: 109
Study 31087325 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of micronized vaginal progesterone once daily
Number of subjects: 109
Study 31087325 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 109
Study 27715351 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast β-glucan 477 mg/capsule
Number of subjects: 44
Study 27715351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27056418 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day MAP treatment
Number of subjects: 45
Study 27056418 — intervention group
Group type: COMPARATOR
Intervention: 14-day MAP treatment
Number of subjects: 45
Study 24372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified enforcement
Number of subjects: 121
Study 24372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Harsh jail penalty
Number of subjects: 121
Study 24372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate long license suspension
Number of subjects: 121
Study 24372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative ways to get home
Number of subjects: 121
Study 24372492 — intervention group
Group type: COMPARATOR
Intervention: Delayed punishment due to judicial processing
Number of subjects: 121
Study 24372492 — intervention group
Group type: COMPARATOR
Intervention: Fine penalty
Number of subjects: 121
Study 24372492 — intervention group
Group type: COMPARATOR
Intervention: Legal blood alcohol concentration (BAC) limit
Number of subjects: 121
Study 24372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Expecting a jail penalty for a DUI offense
Number of subjects: 121
Study 24372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous experience of driving after drinking
Number of subjects: 121
Study 22353899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pre‐ and retro‐auricular incision
Number of subjects: 30
Study 22353899 — intervention group
Group type: COMPARATOR
Intervention: Standard bayonet‐shaped incision
Number of subjects: 30
Study 20373200 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery with visual, kinaesthetic, or visuo‐kinaesthetic imagery (15 and 150 trials)
Number of subjects: 0
Study 20373200 — intervention group
Group type: COMPARATOR
Intervention: Control group with no imagery
Number of subjects: 0
Study 18983730 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cohort studies
Number of subjects: 0
Study 18983730 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 18983730 — intervention group
Group type: COMPARATOR
Intervention: Practice-based studies
Number of subjects: 0
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT vs Tono-Pen XL
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT vs ocular blood flow tonograph (OBF)
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT vs Canon TX-10 non-contact tonometer (NCT)
Number of subjects: 105
Study 15965164 — intervention group
Group type: COMPARATOR
Intervention: GAT observers
Number of subjects: 105
Study 15965164 — intervention group
Group type: COMPARATOR
Intervention: GAT vs Tono-Pen
Number of subjects: 105
Study 15965164 — intervention group
Group type: COMPARATOR
Intervention: GAT vs OBF
Number of subjects: 105
Study 15965164 — intervention group
Group type: COMPARATOR
Intervention: GAT vs NCT
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: OBF
Number of subjects: 105
Study 15965164 — intervention group
Group type: EXPERIMENTAL
Intervention: NCT
Number of subjects: 105
Study 12057882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam restorations
Number of subjects: 507
Study 12057882 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple outcomes
Number of subjects: 507
Study 12057882 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim comparisons
Number of subjects: 507
Study 10489948 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (single section with two anticytokeratins AE‐1 and CAM 5.2)
Number of subjects: 736
Study 10489948 — intervention group
Group type: COMPARATOR
Intervention: Serial sectioning and haematoxylin and eosin (two sections from each of six levels)
Number of subjects: 736
Study 10489948 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 736
Study 10489948 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemically detected occult lymph-node metastases
Number of subjects: 736
Study 8954303 — intervention group
Group type: EXPERIMENTAL
Intervention: Denial of hemiplegia patients
Number of subjects: 20
Study 8954303 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with neglect)
Number of subjects: 20
Study 1492865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC)
Number of subjects: 240
Study 1492865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 3898010 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (10 mg/kg for 2-6 months, 12 mg/kg for 6-12 months, 16 mg/kg for 12-24 months)
Number of subjects: 62
Study 3898010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30481681 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with elimination of safety behaviors (E/ESB)
Number of subjects: 60
Study 30481681 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with judiciously used safety behaviors (E/JU)
Number of subjects: 60
Study 30481681 — intervention group
Group type: COMPARATOR
Intervention: Both E/ESB and E/JU
Number of subjects: 60
Study 29793828 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 53
Study 29793828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose transdermal testosterone gel (1.62%, 1.25 g)
Number of subjects: 53
Study 29793828 — intervention group
Group type: EXPERIMENTAL
Intervention: Full replacement dose testosterone gel (1.62%, 5 g)
Number of subjects: 53
Study 29793828 — intervention group
Group type: EXPERIMENTAL
Intervention: Full replacement dose testosterone gel with aromatase inhibitor
Number of subjects: 53
Study 29793828 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical castration
Number of subjects: 53
Study 29793828 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum 17β-estradiol concentration
Number of subjects: 53
Study 27322115 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training condition with gaze-contingent feedback
Number of subjects: 36
Study 27322115 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 23291316 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention in facilities with part-time NP/PA staffing
Number of subjects: 256
Study 23291316 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid intervention in facilities with no NP/PA staffing
Number of subjects: 256
Study 23291316 — intervention group
Group type: COMPARATOR
Intervention: Full-time NP/PA staffing
Number of subjects: 256
Study 24573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (ascorbic acid and α‐tocopherol)
Number of subjects: 75
Study 24573122 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 75
Study 24573122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamins and n‐3 PUFAs
Number of subjects: 75
Study 24573122 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 24573122 — intervention group
Group type: COMPARATOR
Intervention: n‐3 PUFAs group
Number of subjects: 75
Study 22499570 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg⁻¹)
Number of subjects: 10
Study 22499570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19690659 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcaneal dual energy X-ray laser measurements
Number of subjects: 2884
Study 19690659 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcaneal dual energy X-ray laser T-score
Number of subjects: 2884
Study 19690659 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcaneal DXL and DXA T-scores
Number of subjects: 2884
Study 19690659 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcaneal DXL and DXA Z-scores
Number of subjects: 2884
Study 17333971 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of acetylsalicylic acid (aspirin) ingested 24 hours before blood donation
Number of subjects: 20
Study 17333971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 20
Study 15273633 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide
Number of subjects: 22
Study 15273633 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of furosemide
Number of subjects: 22
Study 11575417 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 microg kg(‐1) followed by an infusion of 0.1 microg kg min(‐1)
Number of subjects: 40
Study 11575417 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg kg(‐1) followed by an infusion of saline
Number of subjects: 40
Study 11575417 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 9827341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on booster
Number of subjects: 44
Study 9827341 — intervention group
Group type: EXPERIMENTAL
Intervention: Video booster
Number of subjects: 44
Study 9827341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 8596961 — intervention group
Group type: EXPERIMENTAL
Intervention: Metsan (Snowchem) and benzylbenzoate
Number of subjects: 60
Study 8596961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress covers (Allergy Control Products)
Number of subjects: 60
Study 8596961 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 1961221 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen plus continuous positive airway pressure
Number of subjects: 39
Study 1961221 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 39